Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mycophenolate Mofetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 known ✓ | P12268 | 19/20 | 0.70 |
| ▸ | IMPDH1 known ✓ | P20839 | 14/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mycophenolate Mofetil SCHEMBL29645056 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29378681 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL4195 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29571382 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL218782 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL23581135 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL10262894 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL1235420 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL2257852 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL3016437 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212177-A1 | COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOPIC AND HETEROPIC XENOGENEIC HEART TRANSPLANTATIONS | Reichart, Bruno (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-4154912-A1 | DONOR ORGANISM FOR XENOGENEIC ORGAN TRANSPLANTS | Reichart, Bruno (DE) | 2023-03-29 | — | — | EP | disclosed |
| US-20210105999-A1 | COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOTOPIC AND HETEROTOPIC XENOGENEIC HEART, KIDNEY, LUNG OR LIVER TRANSPLANTATIONS | REICHART, BRUNO (DE) | 2021-04-15 | — | — | US | disclosed |
| EP-3773570-A2 | COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOPIC AND HETEROPIC XENOGENEIC HEART, KIDNEY, LUNG OR LIVER TRANSPLANTATIONS | Reichart, Bruno (DE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019185936-A2 | METHODS AND COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOTOPIC AND HETEROTOPIC XENOGENEIC HEART, KIDNEY, LUNG OR LIVER TRANSPLANTATIONS | REICHART BRUNO (DE) | 2019-10-03 | — | — | WO | disclosed |
| US-10058641-B2 | Medical devices containing rapamycin analogs | ABBOTT LABORATORIES (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3175870-A1 | MEDICAL DEVICE HAVING HYDRATION INHIBITOR | Abbott Laboratories (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3138531-A1 | COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS USING MEDICAL DEVICES FOR LONG-TERM EFFICACY | Abbott Laboratories (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2358299-B1 | BODY LUMEN FILTER RETRIEVAL SYSTEM AND METHODS FOR FILTERING A BODY LUMEN | ABBOTT LABORATORIES VASCULAR ENTPR LTD (IE) | 2017-02-15 | — | — | EP | disclosed |
| US-9504551-B2 | Apparatus for filtering a body lumen | ABBOTT LABORATORIES VASCULAR ENTERPRISES LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| EP-0877554-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | Merck & Co., Inc. (US) | 1998-11-18 | — | — | EP | disclosed |
| EP-0858456-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0858332-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998016518-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016531-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016532-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1997016438-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997016068-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997016182-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997016437-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10058641-B2 | Medical devices containing rapamycin analogs | PGF, RICTOR, MMP9 | IMPDH2 3448/4885IMPDH1 2543/4885ALDH1A1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.